2023 World Conference on Lung Cancer (Posters)-EP12.01. Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study

EP12.01. Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

A retrospective study comparing the combination of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with either bevacizumab or ramucirumab, both anti-angiogenic agents, in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) was conducted. The study aimed to assess the clinical applications, efficacy, and adverse events of these two different dual combinations in real-world practice.<br /><br />The study included patients with advanced or recurrent NSCLC harboring EGFR mutations who received first-line EGFR TKI therapy in combination with either bevacizumab or ramucirumab. The data was collected from January 2014 to August 2021 at a single medical center in Taiwan.<br /><br />The results showed that bevacizumab plus EGFR TKIs appeared to have better progression-free survival (PFS) compared to ramucirumab combinations in untreated EGFR-mutated metastatic NSCLC. However, larger studies are needed to verify these findings.<br /><br />The study also analyzed the adverse events associated with the two combinations. Hypertension, proteinuria, bleeding, and dermatitis acneiform were among the common adverse events reported. There were some differences in the occurrence of adverse events between the two groups, with a higher incidence of dermatitis acneiform in the bevacizumab group.<br /><br />The research paper also provided references to related studies that have been conducted on bevacizumab and ramucirumab in EGFR-mutated NSCLC, emphasizing the importance of further research in this area.<br /><br />In conclusion, this retrospective study suggests that bevacizumab plus EGFR TKIs may result in better outcomes in terms of PFS compared to ramucirumab combinations in untreated EGFR-mutated metastatic NSCLC. However, more extensive studies are necessary to validate these findings and provide a comprehensive understanding of the clinical applications and adverse events of these dual combinations in real-world practice.

Asset Subtitle

Ruei-Lin Sun

Meta Tag

Speaker Ruei-Lin Sun

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

epidermal growth factor receptor

EGFR

tyrosine kinase inhibitors

TKIs

bevacizumab

ramucirumab

anti-angiogenic agents

non-small cell lung cancer

NSCLC